Molecule
Sodium iodide i-131 is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. It is available as capsules and oral solution. MedsAcross supplies Sodium iodide i-131 for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
HICON ® is indicated for the treatment of hyperthyroidism and selected cases of thyroid carcinoma. HICON ® is a radioactive therapeutic agent indicated for the treatment of hyperthyroidism and selected cases of carcinoma of the thyroid.
Source: US FDA prescribing information
Iodide is actively transported by the sodium-iodide symporter (NIS) protein, in thyroid follicular cells. Iodide is concentrated in follicular cells to levels up to 50 times higher than in the plasma. Iodide is metabolically oxidized by thyroid peroxidase to iodinium (I + ) which in turn iodinates tyrosine residues of thyroglobulin (tri or tetra-iodinated tyrosine). The beta emission of I 131 is responsible for the therapeutic effect.
Source: US FDA prescribing information
The concentrated sodium iodide I 131 solution USP provided with HICON ® must be diluted. See Full Prescribing Information for important administration instructions and dilution and preparation instructions for sodium iodide l 131 capsules or oral solution. The recommended dose is based on the thyroid gland uptake as well as the size of the gland: Treatment of Hyperthyroidism: Recommended dosage is 148 MBq to 370 MBq (4 mCi to 10 mCi). Treatment of Thyroid Carcinoma: Recommended dosage is 1,110 MBq to 3,700 MBq (30 mCi to 100 mCi).
Source: US FDA prescribing information
HICON ® is contraindicated in: Patients with vomiting and diarrhea. Patients with thyroid malignancies shown to have no iodide update, which include the majority of medullary or anaplastic carcinomas. Patients receiving concurrent anti-thyroid therapy. Pregnancy. Lactation. Patients with vomiting and diarrhea. Patients with thyroid malignancies shown to have no iodide uptake. Pregnancy. Lactation.
Source: US FDA prescribing information
Radiation-induced thyroiditis may cause or worsen hyperthyroidism. Consider pre-treatment with anti-thyroid medications. Multiple non-thyroid radiation toxicities, including hematopoietic suppression: Individualize dose and monitor for toxicity. Embryo-Fetal toxicity: May cause severe and irreversible hypothyroidism in the neonate. Verify pregnancy status in females of reproductive potential prior to initiating treatment. Females and males of reproductive potential should use effective contraception. Radiation exposure to breast tissue with lactation: Sodium iodide I 131 concentrates in the breast of lactating women. Discontinue breast feeding at least 6 weeks prior to therapy.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described below and elsewhere in labeling: Radiation-induced Thyroiditis. Radiation-induced Toxicities. Hypersensitivity Reactions. Embryo-Fetal Toxicity. Increased Radiation Exposure to Breast Tissue with Lactation. Transient Infertility. Radiation Exposure to Other Individuals. Risk of Decreased Effectiveness of Therapy. Common adverse reactions reported with therapeutic doses of sodium iodide I 131 include local swelling, radiation sickness, sialadenitis, salivary gland dysfunction, bone marrow depression, lacrimal gland dysfunction, hypothyroidism, hyperthyroidism, thyrotoxic crisis.
Source: US FDA prescribing information
Concomitant use of bone marrow depressants may enhance the depression of the hematopoietic system caused by the use of large doses of sodium iodide I 131. Many drugs and iodide-containing foods interfere with the accumulation of radioiodide by the thyroid. Review the patient’s history, current medications, and recent diagnostic tests prior to the administration of sodium iodide I 131. Advise patients to maintain a low-iodide diet two weeks prior to radioiodide administration and continue for several days during the uptake or imaging process and to discontinue taking the following products before they undergo the procedure as shown in Table 4.
Source: US FDA prescribing information
Store and dispose of HICON ® in compliance with the appropriate regulations of the government agency authorized to license the use of this radionuclide.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Sodium iodide i-131, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Hicon 1000 mCi/mL oral solutionOral | Jubilant RadiopharmaIndia | US FDA | Available on request |
| Sodium Iodide I 131 Diagnostic 100 mCi capsuleOral | Jubilant RadiopharmaIndia | US FDA | Available on request |
2 brand names across 1 markets.
United States
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 2 May 1957 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 2 presentations of Sodium iodide i-131 and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Jubilant Radiopharma.
The catalogue lists 2 brand names for Sodium iodide i-131, including Hicon, Sodium Iodide I 131 Diagnostic.
Yes. The US FDA first approved Sodium iodide i-131 on 2 May 1957, according to Drugs@FDA.
No listed presentation of Sodium iodide i-131 is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Sodium iodide i-131 is classified under ATC code V10XA01 (Sodium iodide i-131).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.